Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas.
Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M, Lang FF. Nakamizo A, et al. Among authors: studeny m. Cancer Res. 2005 Apr 15;65(8):3307-18. doi: 10.1158/0008-5472.CAN-04-1874. Cancer Res. 2005. PMID: 15833864
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.
Palmer DH, Ma YT, Peck-Radosavljevic M, Ross P, Graham J, Fartoux L, Deptala A, Studeny M, Schnell D, Hocke J, Loembé AB, Meyer T. Palmer DH, et al. Among authors: studeny m. Br J Cancer. 2018 May;118(9):1162-1168. doi: 10.1038/s41416-018-0051-8. Epub 2018 Mar 22. Br J Cancer. 2018. PMID: 29563636 Free PMC article. Clinical Trial.
Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment.
Van Cutsem E, Yoshino T, Hocke J, Oum'Hamed Z, Studeny M, Tabernero J. Van Cutsem E, et al. Among authors: studeny m. Clin Colorectal Cancer. 2016 Mar;15(1):91-94.e1. doi: 10.1016/j.clcc.2015.09.005. Epub 2015 Oct 9. Clin Colorectal Cancer. 2016. PMID: 26603056 Clinical Trial.
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.
Van Cutsem E, Prenen H, D'Haens G, Bennouna J, Carrato A, Ducreux M, Bouché O, Sobrero A, Latini L, Staines H, Oum'Hamed Z, Dressler H, Studeny M, Capdevila J. Van Cutsem E, et al. Among authors: studeny m. Ann Oncol. 2015 Oct;26(10):2085-91. doi: 10.1093/annonc/mdv286. Epub 2015 Aug 12. Ann Oncol. 2015. PMID: 26272806 Free article. Clinical Trial.
36 results